The clinical significance of SWI/SNF complex in pancreatic cancer

Numata,Masakatsu; Morinaga,Soichiro; Watanabe,Takuo; Tamagawa,Hiroshi; Yamamoto,Naoto; Shiozawa,Manabu; Nakamura,Yoshiyasu; Kameda,Yoichi; Okawa,Shinichi; Rino,Yasushi; Akaike,Makoto; Masuda,Munetaka; Miyagi,Yohei

doi:10.3892/ijo.2012.1723

The clinical significance of SWI/SNF complex in pancreatic cancer

Authors:
- Masakatsu Numata
- Soichiro Morinaga
- Takuo Watanabe
- Hiroshi Tamagawa
- Naoto Yamamoto
- Manabu Shiozawa
- Yoshiyasu Nakamura
- Yoichi Kameda
- Shinichi Okawa
- Yasushi Rino
- Makoto Akaike
- Munetaka Masuda
- Yohei Miyagi
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Kanagawa Cancer Center, Asahi-ku, Yokohama, Kanagawa 241-0815, Japan, Gastroenterological Center, Yokohama City University Medical Center, Minami-ku, Yokohama, Kanagawa 232-0024, Japan, Department of Surgery, Yokohama City University, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan, Molecular Pathology and Genetics Division, Kanagawa Cancer Center, Asahi-ku, Yokohama, Kanagawa 241-0815, Japan, Department of Pathology, Kanagawa Cancer Center, Asahi-ku, Yokohama, Kanagawa 241-0815, Japan, Department of Hepatobiliary and Pancreatic Medicine, Kanagawa Cancer Center, Asahi-ku, Yokohama, Kanagawa 241-0815, Japan
Published online on: November 30, 2012 https://doi.org/10.3892/ijo.2012.1723
Pages: 403-410
Copyright: © Numata et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chromatin remodeling factors have been the subject of great interest in oncology. However, little is known about their role in pancreatic cancer. The objective of this study was to clarify the clinical significance of the SWItch/sucrose non-fermentable (SWI/SNF) complex in patients with pancreatic cancer. A total of 68 patients with pancreatic cancer who underwent R0, 1 resection were enrolled. Cancer tissues were processed to tissue microarray, then stained immunohistochemically by using antibody of SWI/SNF components; BRM, BRG1, BAF250a, BAF180 and BAF47. The correlation of expression levels and clinicopathological outcomes were analyzed, followed by the multivariate analysis of prognostic factors for overall survival. The expression levels of the SWI/SNF components were categorized as low or high according to the median value of Histoscore. Statistical analysis revealed that BRM expression was related to tumor size, T factor, M factor, lymphatic invasion and stage BRG1 expression to histology and stage BAF180 expression to tumor size and BAF47 expression to lymphatic invasion, respectively. Multivariate Cox proportional hazard analysis showed that high BRM and low BAF180 expression levels were independent predictors of worse survival in patients with pancreatic cancer. High BRM, and low BAF180 were also independent prognostic factors for poor survival in the subgroup with adjuvant gemcitabine. These results suggest that the specific cofactors of SWI/SNF chromatin remodeling complex certainly have roles in pancreatic cancer. High BRM, and low BAF180 are useful biomarkers for poor prognosis in pancreatic cancer.

View Figures

View References

1.	Parkin DM, Bray FI and Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer. 37(Suppl 8): S4–S66. 2001.PubMed/NCBI
2.	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
3.	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar
4.	Reisman DN, Strobeck MW, Betz BL, et al: Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene. 21:1196–1207. 2002. View Article : Google Scholar : PubMed/NCBI
5.	Wade PA: Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet. 10:693–698. 2001. View Article : Google Scholar
6.	Neely KE and Workman JL: The complexity of chromatin remodeling and its links to cancer. Biochim Biophys Acta. 1603:19–29. 2002.PubMed/NCBI
7.	Klochendler-Yeivin A, Muchardt C and Yaniv M: SWI/SNF chromatin remodeling and cancer. Curr Opin Genet Dev. 12:73–79. 2002. View Article : Google Scholar
8.	Davis PK and Brackmann RK: Chromatin remodeling and cancer. Cancer Biol Ther. 2:22–29. 2003. View Article : Google Scholar
9.	Narlikar GJ, Fan HY and Kingston RE: Cooperation between complexes that regulate chromatin structure and transcription. Cell. 108:475–487. 2002. View Article : Google Scholar : PubMed/NCBI
10.	Langst G and Becker PB: Nucleosome mobilization and positioning by ISWI-containing chromatin-remodeling factors. J Cell Sci. 114:2561–2568. 2001.PubMed/NCBI
11.	Kingston RE and Narlikar GJ: ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. Genes Dev. 13:2339–2352. 1999. View Article : Google Scholar : PubMed/NCBI
12.	Burns LG and Peterson CL: The yeast SWI-SNF complex facilitates binding of a transcriptional activator to nucleosomal sites in vivo. Mol Cell Biol. 17:4811–4819. 1997.PubMed/NCBI
13.	Wu C: Chromatin remodeling and the control of gene expression. J Biol Chem. 272:28171–28174. 1997. View Article : Google Scholar : PubMed/NCBI
14.	Breeden L and Nasmyth K: Cell cycle control of the yeast HO gene: cis- and trans-acting regulators. Cell. 48:389–397. 1987. View Article : Google Scholar : PubMed/NCBI
15.	Recht J and Osley MA: Mutations in both the structured domain and N-terminus of histone H2B bypass the requirement for Swi-Snf in yeast. EMBO J. 18:229–240. 1999. View Article : Google Scholar : PubMed/NCBI
16.	Phelan ML, Sif S, Narlikar GJ and Kingston RE: Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell. 3:247–253. 1999. View Article : Google Scholar : PubMed/NCBI
17.	Tyler JK and Kadonaga JT: The ‘dark side’ of chromatin remodeling: repressive effects on transcription. Cell. 99:443–446. 1999.
18.	Wang W, Cote J, Xue Y, et al: Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J. 15:5370–5382. 1996.PubMed/NCBI
19.	Decristofaro MF, Betz BL, Rorie CJ, Reisman DN, Wang W and Weissman BE: Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J Cell Physiol. 186:136–145. 2001. View Article : Google Scholar : PubMed/NCBI
20.	McCarty KS Jr, Miller LS, Cox EB, Konrath J and McCarty KS Sr: Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 109:716–721. 1985.
21.	Bourgo RJ, Siddiqui H, Fox S, et al: SWI/SNF deficiency results in aberrant chromatin organization, mitotic failure, and diminished proliferative capacity. Mol Biol Cell. 20:3192–3199. 2009. View Article : Google Scholar : PubMed/NCBI
22.	Reisman D, Glaros S and Thompson EA: The SWI/SNF complex and cancer. Oncogene. 28:1653–1668. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Wiegand KC, Shah SP, Al-Agha OM, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Jones S, Wang TL, Shih Ie M, et al: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 330:228–231. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Varela I, Tarpey P, Raine K, et al: Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 469:539–542. 2011. View Article : Google Scholar : PubMed/NCBI
26.	Weissman B and Knudsen KE: Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res. 69:8223–8230. 2009. View Article : Google Scholar : PubMed/NCBI
27.	Roberts CW and Orkin SH: The SWI/SNF complex - chromatin and cancer. Nat Rev Cancer. 4:133–142. 2004. View Article : Google Scholar : PubMed/NCBI
28.	Biegel JA, Kalpana G, Knudsen ES, et al: The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res. 62:323–328. 2002.PubMed/NCBI
29.	Heinemann V, Boeck S, Hinke A, Labianca R and Louvet C: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 8:822008. View Article : Google Scholar
30.	El-Rayes BF and Philip PA: A review of systemic therapy for advanced pancreatic cancer. Clin Adv Hematol Oncol. 1:430–434. 2003.PubMed/NCBI
31.	Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar
32.	Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW and Reisman D: The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene. 26:7058–7066. 2007. View Article : Google Scholar : PubMed/NCBI
33.	Reisman DN, Sciarrotta J, Wang W, Funkhouser WK and Weissman BE: Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res. 63:560–566. 2003.PubMed/NCBI
34.	Fukuoka J, Fujii T, Shih JH, et al: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res. 10:4314–4324. 2004. View Article : Google Scholar : PubMed/NCBI
35.	Batsche E, Yaniv M and Muchardt C: The human SWI/SNF subunit Brm is a regulator of alternative splicing. Nat Struct Mol Biol. 13:22–29. 2006. View Article : Google Scholar : PubMed/NCBI
36.	Martin TA, Harrison G, Mansel RE and Jiang WG: The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol. 46:165–186. 2003. View Article : Google Scholar : PubMed/NCBI
37.	Xue Y, Canman JC, Lee CS, et al: The human SWI/SNF-B chromatin-remodeling complex is related to yeast rsc and localizes at kinetochores of mitotic chromosomes. Proc Natl Acad Sci USA. 97:13015–13020. 2000. View Article : Google Scholar : PubMed/NCBI
38.	Maitra A, Wistuba II, Washington C, et al: High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol. 159:119–130. 2001. View Article : Google Scholar
39.	Zabarovsky ER, Lerman MI and Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene. 21:6915–6935. 2002. View Article : Google Scholar : PubMed/NCBI
40.	Xia W, Nagase S, Montia AG, et al: BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res. 68:1667–1674. 2008. View Article : Google Scholar : PubMed/NCBI
41.	Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993. View Article : Google Scholar : PubMed/NCBI
42.	Duns G, Hofstra RM, Sietzema JG, et al: Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum Mutat. 33:1059–1062. 2012. View Article : Google Scholar : PubMed/NCBI
43.	Nie Z, Xue Y, Yang D, et al: A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol Cell Biol. 20:8879–8888. 2000. View Article : Google Scholar : PubMed/NCBI
44.	Sekine I, Sato M, Sunaga N, et al: The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer. Oncogene. 24:2735–2738. 2005. View Article : Google Scholar : PubMed/NCBI
45.	Wang X, Nagl NG Jr, Flowers S, Zweitzig D, Dallas PB and Moran E: Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. Int J Cancer. 112:6362004. View Article : Google Scholar : PubMed/NCBI
46.	Nagl NG Jr, Zweitzig DR, Thimmapaya B, Beck GR Jr and Moran E: The c-myc gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest. Cancer Res. 66:1289–1293. 2006. View Article : Google Scholar : PubMed/NCBI